PriceTargets.com logo

NASDAQ:CLGN - CollPlant Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.00
  • Forecasted Upside: 97.72 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$13.15 As of 03/8/2021 10:48 AM ET
▲ +0.08 (0.61%)
1 month | 3 months | 12 months
Get New CollPlant Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$26.00
▲ +97.72% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CollPlant Biotechnologies in the last 3 months. The average price target is $26.00, with a high forecast of $26.00 and a low forecast of $26.00. The average price target represents a 97.72% upside from the last price of $13.15.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in CollPlant Biotechnologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2021HC WainwrightBoost Price TargetBuy$13.00 ➝ $26.00Low
i
12/2/2020HC WainwrightReiterated RatingBuy$13.00High
i
5/28/2020HC WainwrightReiterated RatingBuy$11.00 ➝ $13.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/3/2020HC WainwrightBoost Price TargetBuy$7.00 ➝ $11.00Low
i
12/3/2019HC WainwrightReiterated RatingBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/27/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/18/2018HC WainwrightInitiated CoverageBuy$7.00High
i
Rating by S. Ramakanth at HC Wainwright
(Data available from 3/8/2016 forward)
CollPlant Biotechnologies logo
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $13.15
$13.15
$13.15

50 Day Range

MA: $16.76
$12.29
$24.25

52 Week Range

Now: $13.15
$6.00
$24.26

Volume

100 shs

Average Volume

165,093 shs

Market Capitalization

$74.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of CollPlant Biotechnologies?

The following equities research analysts have issued research reports on CollPlant Biotechnologies in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for CLGN.

What is the current price target for CollPlant Biotechnologies?

1 Wall Street analysts have set twelve-month price targets for CollPlant Biotechnologies in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 97.7%. HC Wainwright has the highest price target set, predicting CLGN will reach $26.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $26.00 for CollPlant Biotechnologies in the next year.
View the latest price targets for CLGN.

What is the current consensus analyst rating for CollPlant Biotechnologies?

CollPlant Biotechnologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLGN will outperform the market and that investors should add to their positions of CollPlant Biotechnologies.
View the latest ratings for CLGN.

What other companies compete with CollPlant Biotechnologies?

Other companies that are similar to CollPlant Biotechnologies include Milestone Scientific, Lakeland Industries, United Health Products, Nutriband, Surgalign, Sanara MedTech, Alpha Pro Tech, ReWalk Robotics, Conformis, Myomo, Predictive Oncology, Allied Healthcare Products, Advanced Biomedical Technologies, Bionik Laboratories and NanoVibronix.

How do I contact CollPlant Biotechnologies' investor relations team?

CollPlant Biotechnologies' physical mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company's listed phone number is 972-73-232-5600 and its investor relations email address is [email protected] The official website for CollPlant Biotechnologies is www.collplant.com.